Multi-Analyte Panel Development Services: High-Throughput LC-MS/MS Multiplexed Bioanalysis

In the rapidly evolving landscape of drug discovery, the transition from standard LC-MS/MS Single Drug Quantification Services to sophisticated multi-analyte panels has become a necessity for high-throughput PK/PD evaluation. Multi-analyte panel development involves the simultaneous monitoring of multiple parent drugs, their primary and secondary metabolites, or a suite of endogenous biomarkers in a single LC-MS/MS run.

By consolidating diverse chemical entities into a unified analytical framework, researchers can maximize the biological data extracted from limited sample volumes—such as micro-sampling in rodent models or rare biopsies. This approach significantly reduces total run times and solvent consumption while providing a holistic view of the compound’s metabolic fate. Our platform is designed to handle the exponential increase in data complexity that comes with multiplexing, ensuring that each analyte is quantified with the same rigor as a single-analyte assay.

A. Analyte Harmonization & Mobile Phase Engineering

A primary challenge in multi-analyte panels is the "Polarity Gap." For instance, a panel might contain a highly lipophilic parent drug like Cyclosporine A alongside much more polar oxidative metabolites. Using traditional methods often results in the loss of polar species in the solvent front or excessive retention of the parent drug.

Our solution involves the use of sub-2μm column chemistries and precisely engineered mobile phase modifiers. We implement multi-step linear and non-linear gradients that "harmonize" the retention of disparate species, ensuring baseline separation and sharp peak symmetry for all 50+ potential targets within a single window.

B. Suppression of Inter-Analyte Crosstalk & Matrix Effects

Multiplexed assays are inherently susceptible to crosstalk—where the signal from one analyte "leaks" into the MRM channel of another—and ion suppression caused by co-eluting matrix components.

We solve this through Dynamic Transition Selection. By screening multiple precursor-to-product ion transitions for every analyte, we select the most unique and interference-free signatures. Furthermore, we utilize a "Cocktail IS" strategy, ensuring that localized ion suppression is perfectly compensated, maintaining a Precision CV of <15% even in complex Tissue and Cell Lysates.

C. Dynamic Range Management

In early discovery, parent drugs may be present at μg/mL concentrations, while reactive or minor metabolites exist at low pg/mL levels. Our platform maintains linearity across a 4-5 order dynamic range, allowing for the simultaneous quantification of high-abundance and trace-level components in a single injection without the need for multiple dilutions.

We provide instant access to pre-optimized methods for the following compound classes, supporting rapid ADME/PK screening in common Plasma and Serum matrices:

• Anti-Infectives: Multi-class antibiotic panels (β-lactams, aminoglycosides).
• Oncology: Targeted panels for kinase inhibitors (TKIs like Imatinib) and Metabolite Identification (MetID) of cytotoxics.
• Cardiovascular: Screening of lipid-regulators (Atorvastatin) and anticoagulants.
• CNS Agents: High-resolution detection for Diazepam and other BBB-permeable compounds.
• Analgesics: Comprehensive monitoring of parent drugs and metabolic glucuronides.
• Endocrine & Steroids: Baseline separation of 12+ structural steroid isomers.
• Immunosuppressants: Synchronized quantification for Tacrolimus and related macrolides.
• Hepatobiliary Drugs: Focused screening for Omeprazole and Drug–Drug Interaction (DDI) risks.

1. Project Assessment: Reviewing analyte structures, polarities, and required sensitivity ranges.
2. Method Design: Selecting internal standards and optimizing LC-MS/MS parameters for all components.
3. Harmonization & Validation: Verifying separation resolution and assessing inter-analyte interference (crosstalk).
4. High-Throughput Analysis: Executing sample runs using automated preparation to minimize batch-to-batch variability.
5. Data Consolidation: Delivering raw concentration data and integrated PK parameter packages.